Maynard Um
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) PT Raised to $12 at Piper Sandler
-
-
-
-
-
-
-
CytomX reports positive phase 1 data for colorectal cancer treatment
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) Misses Q3 EPS by 4c
-
-
-
-
-
-
-
H.C. Wainwright Upgrades CytomX Therapeutics (CTMX) to Buy, 'EpCAM ADC Data Are Highly Impressive'
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) Tops Q2 EPS by 2c
-
-
396,470 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

